X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (63) 63
male (54) 54
hematology (53) 53
female (51) 51
index medicus (47) 47
middle aged (46) 46
aged (43) 43
adult (37) 37
oncology (25) 25
prognosis (25) 25
survival (25) 25
aged, 80 and over (22) 22
adolescent (21) 21
stem-cell transplantation (16) 16
treatment outcome (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
disease-free survival (15) 15
follow-up studies (15) 15
survival rate (15) 15
multiple myeloma - drug therapy (14) 14
therapy (14) 14
cancer (13) 13
chemotherapy (13) 13
retrospective studies (13) 13
risk factors (13) 13
hematology, oncology and palliative medicine (12) 12
leukemia (11) 11
survival analysis (11) 11
abridged index medicus (10) 10
acute myeloid-leukemia (10) 10
bortezomib (9) 9
leukemia, myeloid, acute - mortality (9) 9
multiple myeloma (9) 9
multiple myeloma - mortality (9) 9
myelodysplastic syndromes (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
child (8) 8
colony-stimulating factor (8) 8
multivariate analysis (8) 8
myelodysplastic syndromes - drug therapy (8) 8
prednisone - administration & dosage (8) 8
remission induction (8) 8
risk (8) 8
transplantation (8) 8
azacitidine (7) 7
bone-marrow transplantation (7) 7
disease (7) 7
elderly (7) 7
melphalan - administration & dosage (7) 7
myelodysplastic syndromes - mortality (7) 7
patients (7) 7
scoring system (7) 7
thalidomide - analogs & derivatives (7) 7
time factors (7) 7
young adult (7) 7
acute myeloid leukemia (6) 6
analysis (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
boronic acids - administration & dosage (6) 6
care and treatment (6) 6
child, preschool (6) 6
criteria (6) 6
diagnosis (6) 6
disease progression (6) 6
immunophenotyping (6) 6
kaplan-meier estimate (6) 6
lenalidomide (6) 6
proportional hazards models (6) 6
prospective studies (6) 6
pyrazines - administration & dosage (6) 6
registries (6) 6
spain (6) 6
thalidomide - administration & dosage (6) 6
abnormalities (5) 5
age factors (5) 5
antineoplastic agents - therapeutic use (5) 5
azacitidine - administration & dosage (5) 5
b-cell lymphoma (5) 5
classification (5) 5
cytogenetic analysis (5) 5
drug administration schedule (5) 5
filgrastim (5) 5
group-b (5) 5
hematopoietic stem cell transplantation - methods (5) 5
karyotype (5) 5
leukemia, myeloid, acute - drug therapy (5) 5
lymphoma (5) 5
lymphomas (5) 5
medical prognosis (5) 5
minimal residual disease (5) 5
myelodysplastic syndrome (5) 5
myelodysplastic syndromes - genetics (5) 5
research (5) 5
thalidomide - therapeutic use (5) 5
transplantation, autologous (5) 5
acute disease (4) 4
aml (4) 4
antimetabolites, antineoplastic - therapeutic use (4) 4
chromosome aberrations (4) 4
cytogenetics (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 5, pp. 438 - 447
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 934 - 941
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2018, Volume 181, Issue 3, pp. 350 - 359
Journal Article
Blood, ISSN 0006-4971, 06/2016, Volume 127, Issue 25, pp. 3165 - 3174
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, p. e0123978
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2013, Volume 163, Issue 5, pp. 581 - 589
Summary Minimal residual disease monitoring is becoming increasingly important in multiple myeloma (MM), but multiparameter flow cytometry (MFC) and... 
flow cytometry | minimal residual disease | IGH | fluorescent‐PCR | Multiple myeloma | Minimal residual disease | Flow cytometry | Fluorescent-PCR | LYMPHOPROLIFERATIONS | AUTOLOGOUS TRANSPLANTATION | REARRANGEMENTS | IMMUNOFIXATION | IMPACT | POLYMERASE-CHAIN-REACTION | THERAPY | fluorescent-PCR | FLOW-CYTOMETRY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Prognosis | Multiple Myeloma - mortality | Humans | Middle Aged | Fluorometry - methods | Male | Transplantation, Autologous | Polymerase Chain Reaction - economics | Polymerase Chain Reaction - methods | Neoplasm, Residual | Multiple Myeloma - drug therapy | Clinical Trials, Phase III as Topic - statistics & numerical data | Diagnostic Tests, Routine - economics | Sensitivity and Specificity | Flow Cytometry - economics | Aged, 80 and over | Adult | Female | Gene Rearrangement, B-Lymphocyte, Light Chain | Multiple Myeloma - surgery | Multicenter Studies as Topic - statistics & numerical data | Hematopoietic Stem Cell Transplantation | Immunophenotyping | Genes, Immunoglobulin | Multiple Myeloma - pathology | Gene Rearrangement, B-Lymphocyte, Heavy Chain | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | DNA, Neoplasm - genetics | Fluorometry - economics | Multiple Myeloma - genetics | Genetic research | Immunoglobulins | Genetic aspects | Genes | Cancer
Journal Article
Journal Article